1. Home
  2. SUNC vs BLLN Comparison

SUNC vs BLLN Comparison

Compare SUNC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SunocoCorp LLC

SUNC

SunocoCorp LLC

HOLD

Current Price

$75.79

Market Cap

4.2B

Sector

N/A

ML Signal

HOLD

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$125.00

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNC
BLLN
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.4B
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
SUNC
BLLN
Price
$75.79
$125.00
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$61.00
★ $126.71
AVG Volume (30 Days)
370.4K
★ 523.3K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
★ 5.74%
N/A
EPS Growth
N/A
★ 103.40
EPS
★ 2.89
0.48
Revenue
★ $25,201,000,000.00
$305,112,000.00
Revenue This Year
$65.29
$46.29
Revenue Next Year
$0.84
$30.14
P/E Ratio
★ $26.74
$260.21
Revenue Growth
11.05
★ 99.97
52 Week Low
$47.00
$61.96
52 Week High
$83.50
$150.44

Technical Indicators

Market Signals
Indicator
SUNC
BLLN
Relative Strength Index (RSI) 41.78 69.01
Support Level $74.68 $79.07
Resistance Level $78.21 $150.44
Average True Range (ATR) 2.10 6.54
MACD -0.74 3.25
Stochastic Oscillator 4.04 92.38

Price Performance

Historical Comparison
SUNC
BLLN

About SUNC SunocoCorp LLC

SunocoCorp LLC is a publicly traded limited liability company that owns a direct limited partner interest in Sunoco LP. It engages in the management and distribution of fuel products. It operates through the following segments: Fuel Distribution, Pipeline Systems, and Terminals and Refinery.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: